What is Chardan Capital’s Estimate for CRSP FY2025 Earnings?
CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Equities researchers at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now forecasts that the company will earn ($4.60) per share for the year, up from their […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Equities researchers at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now forecasts that the company will earn ($4.60) per share for the year, up from their […]
